Clinical Trial

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-12-03; most recent amendment 2025-03-06.
Trial Details
NCT Number NCT05646524
Lead Sponsor NovelMed Therapeutics
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 12 participants
Start Date 2026-04
Primary Completion 2027-08 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-03-11